Bliss GVS Pharma Reports ₹96.87 Cr Profit for Fiscal Year 2026, Recommends 100% Dividend

The company's Board of Directors met on May 12, 2026, to approve audited financial results for the year ending March 31, 2026. They recommended a final dividend of 100%, or ₹1 per share, pending shareholder approval at the AGM on July 15, 2026. The meeting will be held via video conference. BDO India Services Private Limited was reappointed as Internal Auditor for fiscal year 2026-27, and auditors provided a clean report.

Strategic Shifts and Shareholder Returns

The proposed dividend offers shareholders a direct return, highlighting the company's financial performance. The sale of a majority stake in its Nigerian subsidiary marks a significant strategic change, influencing group financial reports and operations. Meanwhile, establishing new subsidiaries in Kenya and the Democratic Republic of Congo signals plans to expand into new African markets.

African Market Expansion and Divestment

Bliss GVS Pharma manufactures and markets pharmaceutical formulations and APIs, with a significant presence in African markets. In late fiscal year 2025, the company sold a 51% stake in its Nigerian subsidiary, Greenlife Bliss Healthcare Ltd., for $1.3 million. This divestment led to a loss of control and the subsidiary's exclusion from consolidated financials. In parallel, late in 2025, Bliss GVS Pharma launched two new wholly-owned subsidiaries in Kenya and the Democratic Republic of Congo. Additionally, the implementation of New Labour Codes during FY26 resulted in an increase in employee benefit expenses.

Impact on Shareholders and Group Structure

Shareholders could receive a ₹1 per share dividend if approved at the AGM. The group's consolidated financial reports will now show the effects of selling the Nigerian subsidiary and the performance of new ventures in Kenya and the DRC. The company is adjusting its strategy to concentrate on core markets while exploring new African regions.

Key Challenges and Future Growth

Close monitoring is needed for the full financial impact of the Nigerian subsidiary no longer being consolidated. The successful integration and growth of the new subsidiaries in Kenya and the DRC are crucial. Higher employee benefit costs from the New Labour Codes may also affect future profit margins.

Employee Benefit Costs Detail

Employee benefit expenses increased due to the New Labour Codes. This added ₹215.55 lakh on a standalone basis and ₹248.71 lakh on a consolidated basis for fiscal year 2026.

Investor Focus Points

Investors will track the shareholder vote on the dividend at the July 15, 2026, AGM. Key indicators for future growth will be the financial performance and strategic development of the new subsidiaries in Kenya and the DRC. The long-term effects of the Nigerian subsidiary sale on the company's overall strategy and profitability are also important.